JPMorgan lowers recession probability after Trump's tariff truce with China
The president announced Monday that a deal has been reached to lower the "reciprocal" tariffs he imposed to lower the overall tariff rate on Chinese goods from 145% to 30% for 90 days while negotiators work to finalize a longer-term agreement. The Chinese government, in turn, reduced its retaliatory tariffs on U.S. goods from 125% to 20% for the 90-day period.
"The administration's recent dialing down of some of the more draconian tariffs placed on China should reduce the risk that the U.S. economy slips into recession this year," wrote Michael Feroli, chief U.S. economist at JPMorgan. "Conditioned on current rates prevailing indefinitely, we are now projecting real GDP growth for this year at 0.6% (4Q/4Q), up from 0.2% before the latest tariff news."
"We believe recession risks are still added, but now below 50%," Feroli noted. The firm's prior forecast put the risk of a recession this year at 60% in the days after the Trump administration's "reciprocal" tariff announcement.
White House Slashes 'De Minimis' Tariffs On China To 54%
JPMorgan's analysis projected that the personal consumption expenditure (PCE) index — the Federal Reserve's preferred inflation gauge — will be 3.5% at the end of this year, lower than the estimate of 4% before the tariff pause, but higher than the 2.2% projection from the start of the year.
Read On The Fox Business App
A PCE reading of 3.5% would be well above the Fed's inflation target of 2%, making it more likely the Fed would delay interest rate cuts unless the labor market starts to deteriorate. The unemployment rate was 4.2% in April, and JPMorgan projects the unemployment rate will peak at 4.8% in the second quarter of 2026.
China Criticizes Us-uk Trade Deal, Says It's 'Basic Principle' Not To Target Other Countries: Report
"We still project a modest contraction in employment later this year, as labor demand is projected to slow even more than labor supply," Feroli wrote. "Our updated labor market outlook is less demanding of immediate action to stem employment risks; for the Fed, we are pushing back the timing of the resumption of rate cuts from September to December."
He added that the bank sees three further sequential rate cuts after December, which would lower the target range for the benchmark federal funds rate to a range of 3.25% to 3.5% by the second quarter of 2026.
Trump Says China Deal Will Open Up Market For Us Businesses
The report noted that the changes to tariffs on Chinese goods lowered the average effective tariff rate from around 24% to about 14%, a notable reduction though it remains well above the 2.3% effective tariff rate that prevailed in 2024.
"A tariff is a tax, and so relative to prior assumptions this can be seen as a tax cut of almost $300 billion," Feroli wrote. "Most of that tax was likely to have been borne by U.S. consumers in the form of higher prices."
"The rolling back of this tax should provide some relief to consumer spending, and in our modeling is enough to tip the second-half growth outlook from one of modest contraction to one of modest growth," he added.Original article source: JPMorgan lowers recession probability after Trump's tariff truce with China
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland and the US. At present, there are approximately 123 actively enrolling sites globally. According to the latest data collected by the European Cancer Information System (click here), a total of 12,861 new cases of breast cancer were diagnosed in Romania in 2022, which is the most common cancer diagnosed in women, representing approximately 28% of all cancers in women. Breast cancer is the leading cause of death from cancer in women in Romania with 3,877 deaths in 2022. The Company is collaborating with Dr. Nicoleta Antone, who is leading one of the largest academic breast cancer focused centers in Cluj Napoca, Romania, and her colleagues from at least 3 other sites in Romania. The Romanian clinical sites will be listed here with an interactive map. Dr. Antone will be serving as the national principal investigator in Romania for FLAMINGO-01. She is Head of Breast Cancer Centre at the Chiricuta Institute of Oncology in Cluj Napoca, Romania. She has been the Chair of the Romania Breast Cancer Group since 2021 and a member of the Women's Empowerment Cancer Advocacy Network since 2015. CEO Snehal Patel commented, "Romania is the first of several additional countries in Europe that we hope to add to Flamingo-01 as we now focus on mid-sized population countries with large population centers. We have visited the sites in Romania multiple times to assess study feasibility and provide training, and we are impressed with their facilities and commitment to the study. We look forward to working with Dr. Antone and her colleagues and have sufficiently advanced start-up activities this summer to be potentially screening and enrolling our first Romanian patients in the coming months." About FLAMINGO-01 and GLSI-100 FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients will be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types will be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. For more information on FLAMINGO-01, please visit the Company's website here and here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: flamingo-01@ About Breast Cancer and HER2/ Positivity One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. About Greenwich LifeSciences, Inc. Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company's website at and follow the Company's Twitter at Forward-Looking Statement Disclaimer Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law. Company ContactSnehal PatelInvestor RelationsOffice: (832) 819-3232Email: info@ Investor & Public Relations Contact for Greenwich LifeSciencesDave GentryRedChip Companies 1-800-RED CHIP (733 2447)Email: dave@ in to access your portfolio
Yahoo
2 minutes ago
- Yahoo
Crypto is having a breakout summer — and bitcoin isn't the reason: Morning Brief
Riding high from a series of legislative wins and a wave of new financial initiatives, crypto investors are on the up and up. Another blast of positive catalysts has given the crypto world even more room to run this week. And most notably, the big news items don't really involve bitcoin. Circle (CRCL), the issuer of the second-largest stablecoin, posted better-than-expected quarterly revenue for the first time since going public. Bitmine (BMNR), an Ethereum treasury company, announced plans to sell up to another $20 billion worth of stock to boost its holdings of the cryptocurrency. And an array of popular altcoins are gaining ground. The moves collectively reflect the warm embrace of the Trump administration, which has championed the crypto industry and shifted the regulatory environment long seen as an obstacle to the adoption and growth of digital currency. But the success of Wall Street's crypto hedges also underscores rising institutional interest. Despite the risks, and perhaps because of them, more investors are growing comfortable with crypto exposure. And companies are chasing the returns of amassing tokens in a feedback loop that, however fleeting and precarious, seems to be paying off. Sign up for the Yahoo Finance Morning Brief By subscribing, you are agreeing to Yahoo's Terms and Privacy Policy Home to the fastest-growing major stablecoin over the past year, Circle shares are up more than 400% from its IPO price of $31 per share. As our colleague Ines Ferré reported, the company has been at the center of optimism over the stablecoin market following the passage of the GENIUS Act, legislation that creates a framework for digital tokens backed by assets such as the US dollar. Circle makes much of its money from interest income, specifically from short-term Treasury bills backing its stablecoin, USDC. After announcing a new blockchain network for stablecoin finance on Tuesday, shares rose another 3%. It's a play that could deliver some of crypto's promise for innovation to the financial services industry, and Wall Street and investors are paying attention — and making sure they're involved. Bitmine's surge highlights another pillar of crypto's ascendance in the financial world: the rise of crypto treasury companies. Riffing off the playbook of Strategy (MSTR), which sells new shares and debt to buy and hold more bitcoin, other players are finding success by accumulating other currencies, like ethereum. Bitmine, whose board is led by investor Tom Lee, announced this week that its holdings of ETH now account for roughly 1% of all tokens in circulation, sending the stock up more than 14%. The company's goal is to eventually reach 5% of the world's outstanding ETH tokens. Shares have surged over 600% this year. As this newsletter has written recently, the crypto accumulation strategy isn't working for every imitator, but it does work, as bitcoin continues to climb. But it's not just the dominant tokens that are gaining steam. Over the past week, the 10 largest digital currencies, according to data from CoinMarketCap, have gained. As our colleague Jake Conley reported, Ripple ( and Chainlink (LINK-USD) are among the altcoins rallying, fueled by an acquisition of a payment platform and the launch of a token reserve, respectively. The heady action seems far removed from the crypto winters of the past. But if this is the dawn of a new financial system, as crypto bulls like to profess, this summer is making it a lot easier to make that case. Hamza Shaban is a reporter for Yahoo Finance covering markets and the economy. Follow Hamza on X @hshaban. Click here for in-depth analysis of the latest stock market news and events moving stock prices
Yahoo
2 minutes ago
- Yahoo
Best CD rates today, August 13, 2025 (Lock in up to 5.5% APY)
The Federal Reserve lowered the federal funds three times in 2024. As a result, deposit account rates are on the decline. The good news: You can lock in a competitive return on a certificate of deposit (CD) today and preserve your earning power. In fact, the best CDs still pay rates above 4%. Read on for a snapshot of CD rates today and where to find the best offers. Where are the best CD rates today? CDs today typically offer rates significantly higher than traditional savings accounts. Currently, the best short-term CDs (six to 12 months) generally offer rates around 4.00% to 4.50% APY. As of August 13, 2025, the highest CD rate is 5.5% APY, offered by Gainbridge® on its 5-year CD. There is a $1000 minimum opening deposit required. The following is a look at some of the best CD rates available today from our verified partners. This embedded content is not available in your region. Historical CD rates The 2000s were marked by the dot-com bubble and later, the global financial crisis of 2008. Though the early 2000s saw relatively higher CD rates, they began to fall as the economy slowed and the Federal Reserve cut its target rate to stimulate growth. By 2009, in the aftermath of the financial crisis, the average one-year CD paid around 1% APY, with five-year CDs at less than 2% APY. The trend of falling CD rates continued into the 2010s, especially after the Great Recession of 2007-2009. The Fed's policies to stimulate the economy (in particular, its decision to keep its benchmark interest rate near zero) led banks to offer very low rates on CDs. By 2013, average rates on 6-month CDs fell to about 0.1% APY, while 5-year CDs returned an average of 0.8% APY. However, things changed between 2015 and 2018, when the Fed started gradually increasing rates again. At this point, there was a slight improvement in CD rates as the economy expanded, marking the end of nearly a decade of ultra-low rates. However, the onset of the COVID-19 pandemic in early 2020 led to emergency rate cuts by the Fed, causing CD rates to fall to new record lows. The situation reversed following the pandemic as inflation began to spiral out of control. This prompted the Fed to hike rates 11 times between March 2022 and July 2023. In turn, this led to higher rates on loans and higher APYs on savings products, including CDs. Fast forward to September 2024 — the Fed finally decided to start cutting the federal funds rate after it determined that inflation was essentially under control. Today, we're beginning to see CD rates come down from their peak. Even so, CD rates remain high by historical standards. Take a look at how CD rates have changed since 2009: Understanding today's CD rates Traditionally, longer-term CDs have offered higher interest rates compared to shorter-term CDs. This is because locking in money for a longer period typically carries more risk (namely, missing out on higher rates in the future), which banks compensate for with higher rates. However, this pattern doesn't necessarily hold today; the highest average CD rate is for a 12-month term. This indicates a flattening or inversion of the yield curve, which can happen in uncertain economic times or when investors expect future interest rates to decline. Read more: Short- or long-term CD: Which is best for you? How to choose the best CD rates When opening a CD, choosing one with a high APY is just one piece of the puzzle. There are other factors that can impact whether a particular CD is best for your needs and your overall return. Consider the following when choosing a CD: Your goals: Decide how long you're willing to lock away your funds. CDs come with fixed terms, and withdrawing your money before the term ends can result in penalties. Common terms range from a few months up to several years. The right term for you depends on when you anticipate needing access to your money. Type of financial institution: Rates can vary significantly among financial institutions. Don't just check with your current bank; research CD rates from online banks, local banks, and credit unions. Online banks, in particular, often offer higher interest rates than traditional brick-and-mortar banks because they have lower overhead costs. However, make sure any online bank you consider is FDIC-insured (or NCUA-insured for credit unions). Account terms: Beyond the interest rate, understand the terms of the CD, including the maturity date and withdrawal penalties. Also, check if there's a minimum deposit requirement and if so, that fits your budget. Inflation: While CDs can offer safe, fixed returns, they might not always keep pace with inflation, especially for longer terms. Consider this when deciding on the term and amount to invest.
